In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Soy petition withdrawal

This article was originally published in The Tan Sheet

Executive Summary

The Solae Company is formally withdrawing from further consideration the qualified health claim petition linking soy protein consumption to prevention of cancer, the company confirms in a recent letter to the agency. "The nutrition science pertaining to the health benefits of soy protein is substantial and continues to evolve," and "serves as a catalyst for futher scientific investigation," Solae states. The firm has "closely monitored recent FDA actions with respect to certain qualified health claims. With the benefit of this information, the Solae Company respectifully reserves the option to resubmit a qualified health claim petition centering on soy protein and cancer prevention in the future." The firm also is "most appreciative of the deliberate fashion in which FDA reviewed" its petition, which it announced was under review in April 2004 (1"The Tan Sheet" April 19, 2004, In Brief)...

You may also be interested in...

Soy claims

Solae Company's petition for health claims that soy protein-based foods may reduce the risk of certain types of cancer is being reviewed by FDA, the St. Louis based firm announced April 16. The petition cites 58 studies supporting the relationships, Solae says. The DuPont/Bunge joint venture is "looking forward to the agency's evaluation"...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts